Black Diamond Therapeutics (BDTX) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Diamond Therapeutics is the larger company by market cap ($103.7 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | PLYX |
|---|---|---|
| Share price | $1.81 | $2.00 |
| Market cap | $103.72M | $99.69M |
| 1-day change | -1.09% | -4.31% |
| YTD return | -25.51% | — |
| 1-year return | -54.64% | — |
| 5-year return | -77.87% | — |
| EPS (TTM) | $-0.75 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $48.91 |
| 52-week low | $1.60 | $1.85 |
| Distance from 52-week high | -63.36% | -95.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +452.49% | +275.00% |
| Average volume | 624.32K | 76.41K |
| Shares outstanding | 57.30M | 49.85M |
| Employees | 21 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
BDTX vs PLYX FAQ
Which is bigger, Black Diamond Therapeutics or Polaryx Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $103.72M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Black Diamond Therapeutics and Polaryx Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Black Diamond Therapeutics and Biotechnology: Pharmaceutical Preparations for Polaryx Therapeutics.